A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Active:	No
Cancer Type:	Breast Cancer Cervical Cancer Gynecologic Cancers Head and Neck Cancer Ovarian Cancer	NCT ID:	NCT04682431
Trial Phases:	Phase I	Protocol IDs:	PY159-2-01 (primary) NCI-2021-01998
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Ikena Oncology
NCI Full Details:	http://clinicaltrials.gov/show/NCT04682431

Summary

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in
subjects with locally advanced (unresectable) and/or metastatic solid tumors that are
refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for
that indication).

Objectives

Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard
3+3 design Part B: Dose expansion of one or more dose levels of PY159 administered alone and
in combination with pembrolizumab for predefined tumor histology

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.